08 maj: COOL KARAFLER
09 maj: Pas på de skjulte forsikringer
08-05-2012 21:32:00

CME CEO: Commitment From CME To Draw Business To Dubai Merc

Relateret indhold

By Jacob Bunge

Of DOW JONES NEWSWIRES

Trading on a small Dubai futures market backed by CME Group Inc. (CME) could pick up more steam after the Chicago-based exchange operator boosted its stake in the platform earlier this year, according to CME's new chief executive.

Potential customers had wanted CME to strengthen its commitment to the Dubai Mercantile Exchange before they embraced the market's crude oil futures contract, according to Phupinder Gill, who took over as CEO of CME last week.

CME's prior 25% stake in the Dubai Mercantile Exchange was seen by some traders as translating to a "lack of commitment" by the world's largest exchange operator, Gill told investors in a presentation Tuesday.

The move by CME in February to boost its stake to 50% "could cause them to take on the contract on the DME," said Gill, who has played a key role in managing CME's international alliances in his prior role as president.

The DME reported a trading record Tuesday for the month of April with more than 123,000 contracts changing hands, topping a record set in March by 9%. By comparison, CME's New York Mercantile Exchange division, the company's main hub for energy trading, saw 1.6 million contracts change hands per day last month.

The DME's flagship market is in Oman sour crude futures, which the exchange and CME have sought to position as a better tool for pricing the variety of oil produced in the Middle East versus the sweeter West Texas Intermediate variety traded on the Nymex and the Brent oil contract offered by rival IntercontinentalExchange Inc. (ICE).

While Oman futures trading has grown, only the relatively small Gulf producers Dubai and Oman use the contract to price their oil exports. Major exporters Saudi Arabia, Kuwait, Abu Dhabi, Iraq and Iran all use the Dubai and Oman crude assessments published by Platts, a division of McGraw-Hill when setting their official selling prices for crude sales to the booming Asian region.

At the same time that CME raised its stake in the DME to 50% in late February, the Oman Investment Fund raised its holding to 29% from 25%. The balance of 12% is held on a non-voting basis by strategic investors that include Vitol, Royal Dutch Shell PLC (RDSA, RDSA.LN), J.P. Morgan Chase & Co. (JPM), Morgan Stanley (MS), Goldman Sachs Group Inc. (GS) and Concord Energy.

Trading volumes on the DME last year climbed 19% over 2010 levels, with an average 3,505 contracts traded a day.

-By Jacob Bunge, Dow Jones Newswires; 312 750 4117; jacob.bunge@dowjones.com

--Summer Said and Iman Dawoud contributed to this article.

(END) Dow Jones Newswires

May 08, 2012 15:32 ET (19:32 GMT)

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Novo: Lægemiddelkomité anbefaler godkendelse af Ozempic i Europa - NY2

15-12-2017 13:19:21
Novo Nordisk har fået en vigtig anbefaling fra en lægemiddelkomité under de europæiske sundhedsmyndigheder, EMA, der anbefaler GLP-1-håbet Semaglutid godkendt på det europæiske marked.Semaglutid, der skal markedsføres under navnet Ozempic, skal først officielt godkendes af EMA og EU-Kommissionen, før midlet kan ryge på markedet, men en positiv anbefaling fra lægemiddelkomitéen er som oftest også l..

Aktier/middag: H+H til tops mens C20 går i rødt

15-12-2017 11:41:22
Humøret er vrissent på børserne i Europa fredag, og ved middagstid er det danske C20 Cap-indeks ingen undtagelse, da det falder 0,9 pct. til 1121,34 - især trukket ned af Novo Nordisk.Uden for eliteindekset belønnes H+H International dog pænt for et virksomhedsopkøb til 800 mio. kr., der vil løfte selskabets omsætning med en halv milliard.USA SPREDER DÅRLIG STEMNINGDen generelle nedturen følger i ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo/DZ: Sænker anbefaling til "sælg" fra "hold"
2
Fredagens aktier: Lille aktie kom i rampelyset på rød dag for C20
3
Vestas/Senator: Aftale afskærmer stort set også vind fra Beat-skat
4
Genmab/Jyske: Kursmålet trimmes til 1600 kr. - NY
5
Novo: Lægemiddelkomité anbefaler godkendelse af Ozempic i Europa - NY2

Relaterede aktiekurser

JP Morgan Chase & Co 106,14 1,4% Stigning i aktiekurs
Royal Dutch Shell PLC 'A.. 2.428,50 1,4% Stigning i aktiekurs
Royal Dutch Shell PLC 'B.. 2.452,50 0,9% Stigning i aktiekurs
Morgan Stanley 53,10 0,9% Stigning i aktiekurs
Goldman Sachs Group Inc .. 257,17 0,7% Stigning i aktiekurs
CME Group Inc 151,07 0,4% Stigning i aktiekurs
Royal Dutch Shell PLC Ro.. 64,70 0,2% Stigning i aktiekurs
Royal Dutch Shell PLC Ro.. 66,23 -0,2% Fald i aktiekurs
Royal Dutch Shella 27,68 1,0% Stigning i aktiekurs
Royal Dutch Shellb 28,10 -0,1% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
15. december 2017 22:34:55
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB4 - 2017-12-15 22:34:55 - 2017-12-15 22:34:55 - 1 - Website: OKAY